Blincyto's label has gradually been extended since 2014, and in December the MHRA approved it as the first immunotherapy for ...

At two Senate confirmation hearings, Kennedy played down his well-publicised questioning of the safety of childhood vaccines ...

The week has ended with a flurry of M&A in the drug industry, with Cosette Pharmaceuticals agreeing to buy Australia's Mayne ...

At JP Morgan 2025, pharmaphorum editor-in-chief Jonah Comstock spoke with Ryan Spencer, whose company Dynavax technologies is ...

An inhaled gene therapy for cystic fibrosis developed by Boehringer Ingelheim is due to start clinical testing shortly, hoping to become a first-in-class treatment for the genetic disorder.

A proposed merger of the UK's Poolbeg Pharma with Austrian biotech Hookipa has been called off after the latter abruptly withdrew from negotiations. The news was announced in a stock exchange filing ...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

Around 75% of rare diseases are diagnosed in childhood, with most before the age of two. With 30% of rare disease patients ...

Pharma industry leaders are scheduled to meet with Donald Trump later today to discuss a range of issues affecting the sector ...

NICE's initial guidance on Breyanzi concluded it was not a cost-effective option for patients, but the agency said this ...

The drug is the first non-cannabinoid option for patients with LGS and an alternative to Jazz Pharma's Epidyolex (cannabidiol ...

AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) already has ...